# US 2021/0009705 A1 · Anti-ox40 antibodies and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0009705 A1
- Document ID: US20210009705A1
- Status: Published application
- Kind: A1
- Application number: 16/911,229
- Filed: 2020-06-24
- Published: 2021-01-14
- Earliest claimed: 2014-03-31
- Assignees: Genentech, Inc.
- Applicants: Genentech, Inc.
- Inventors: Changchun DU; Jeong KIM; Jing ZHU; Jack BEVERS, III; Kevin WALSH; Patricia DE ALMEIDA; James ANDYA; Ye SHEN
- Web page: https://patentgrep.com/patent/US20210009705A1

## CPC

- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/22: against growth factors {; against growth regulators}
- C07K 16/30: from tumour cells
- C07K 16/3015: {Breast}
- C07K 16/3023: {Lung}
- C07K 16/303: {Liver or Pancreas}
- C07K 16/3038: {Kidney, bladder}
- C07K 16/3046: {Stomach, Intestines}
- C07K 16/3069: {Reproductive system, e.g. ovaria, uterus, testes, prostate}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/51: Complete heavy chain or Fd fragment, i.e. VH + CH1
- C07K 2317/515: Complete light chain, i.e. VL + CL
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C12N 5/10: Cells modified by introduction of foreign genetic material
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N 15/64: General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
- C12N 15/70: Vectors or expression systems specially adapted for E. coli
- C12N 15/79: Vectors or expression systems specially adapted for eukaryotic hosts
- C12N 2800/00: Nucleic acids vectors
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention provides anti-OX40 antibodies and methods of using the same.

## Claims

### Claim at position 1

1-70. (canceled)

### Claim 71

A method of treating an individual having cancer comprising administering to the individual an effective amount of an anti-human OX40 agonist antibody, wherein the antibody comprises:
(1) a heavy chain variable domain (VH) comprising (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:2; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:3; and (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:4; and
(2) a light chain variable domain (VL) comprising (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:5; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:6; and (f) an HVR-L3 comprising an amino acid sequence of SEQ ID NO:7.

### Claim 72 (depends on 71)

The method of claim 71, further comprising administering an additional therapeutic agent.

### Claim 73 (depends on 72)

The method of claim 72, wherein the additional therapeutic agent comprises a chemotherapeutic agent.

### Claim 74 (depends on 72)

The method of claim 72, wherein the additional therapeutic agent comprises a PD-1 axis binding antagonist.

### Claim 75

A method for treating or delaying progression of cancer in an individual comprising administering to the individual an effective amount of an anti-angiogenesis agent and an OX40 binding agonist; wherein the OX40 binding agonist is an anti-human OX40 agonist antibody comprising:
(1) a heavy chain variable domain (VH) comprising (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:2; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:3; and (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:4; and
(2) a light chain variable domain (VL) comprising (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:5; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:6; and (f) an HVR-L3 comprising an amino acid sequence of SEQ ID NO:7.

### Claim 76

(canceled)

### Claim 77

(canceled)

### Claim 78 (depends on 75)

The method of claim 75, wherein the anti-angiogenesis agent is an anti-angiogenesis antibody.

### Claim 79 (depends on 78)

The method of claim 78, wherein the anti-angiogenesis antibody is a monoclonal antibody.

### Claim 80 (depends on 78)

The method of claim 78, wherein the anti-angiogenesis antibody is a human or humanized antibody.

### Claim 81 (depends on 75)

The method of claim 75, wherein the anti-angiogenesis agent is a VEGF antagonist.

### Claim at position 13

82-90. (canceled)

### Claim 91 (depends on 81)

The method of claim 81, wherein the VEGF antagonist is an anti-VEGF antibody.

### Claim 92 (depends on 91)

The method of claim 91, wherein the anti-VEGF antibody is a human or humanized antibody.

### Claim at position 16

93-107. (canceled)

### Claim 108 (depends on 71)

The method of claim 71, wherein the OX40 agonist antibody is a full-length human IgG1 antibody.

### Claim 109 (depends on 71)

The method of claim 71, wherein the OX40 agonist antibody depletes cells that express human OX40.

### Claim 110 (depends on 109)

The method of claim 109, wherein the cells are CD4+ effector T cells.

### Claim 111 (depends on 109)

The method of claim 109, wherein the cells are Treg cells.

### Claim 112 (depends on 109)

The method of claim 109, wherein the depleting is by ADCC or phagocytosis.

### Claim 113 (depends on 112)

The method of claim 112, wherein the depleting is by ADCC.

### Claim at position 23

114-146. (canceled)

### Claim 147 (depends on 71)

The method of claim 71, wherein the OX40 agonist antibody comprises a VH sequence of SEQ ID NO: 56.

### Claim 148 (depends on 71)

The method of claim 71, wherein the OX40 agonist antibody comprises a VL sequence of SEQ ID NO: 57.

### Claim 149 (depends on 71)

The method of claim 71, wherein the OX40 agonist antibody comprises a VH sequence of SEQ ID NO:56 and a VL sequence of SEQ ID NO: 57.

### Claim at position 27

150-156. (canceled)

### Claim 157 (depends on 71)

The method of claim 71, wherein the cancer is lung cancer, glioblastoma, cervical cancer, ovarian cancer, breast cancer, colon cancer, colorectal cancer, fallopian tube cancer, peritoneal cancer, kidney cancer, renal cancer, non-Hodgkins lymphoma, prostate cancer, pancreatic cancer, soft-tissue sarcoma, kaposi's sarcoma, carcinoid carcinoma, head and neck cancer, mesothelioma, multiple myeloma, non-small cell lung cancer, neuroblastoma, melanoma, gastric cancer, or liver cancer.

### Claim 158 (depends on 71)

The method of claim 71, wherein the cancer is a gynecologic cancer.

### Claim 159 (depends on 71)

The method of claim 71, wherein the cancer is advanced, refractory, recurrent, chemotherapy-resistant, and/or platinum-resistant.

### Claim 160 (depends on 75)

The method of claim 75, wherein the individual has cancer or has been diagnosed with cancer.

### Claim 161 (depends on 71)

The method of claim 71, wherein the treatment results in a sustained response in the individual after cessation of the treatment.

### Claim 162 (depends on 75)

The method of claim 75, wherein the OX40 binding agonist is administered before the anti-angiogenesis agent, simultaneous with the anti-angiogenesis agent, or after the anti-angiogenesis agent.

### Claim 163 (depends on 71)

The method of claim 71, wherein the individual is a human.

### Claim 164 (depends on 75)

The method of claim 75, wherein the anti-angiogenesis agent and/or the OX40 binding agonist are administered intravenously, intramuscularly, subcutaneously, intracerobrospinally, topically, orally, transdermally, intraperitoneally, intraorbitally, by implantation, by inhalation, intrathecally, intraventricularly, intra-articularly, intrasynovially, or intranasally.

### Claim 165 (depends on 75)

The method of claim 75, further comprising administering a chemotherapeutic agent for treating or delaying progression of cancer.

### Claim at position 37

166-173. (canceled)

### Claim 174 (depends on 75)

The method of claim 75, wherein the OX40 agonist antibody is a full-length human IgG1 antibody.

### Claim 175 (depends on 75)

The method of claim 75, wherein the OX40 agonist antibody depletes cells that express human OX40.

### Claim 176 (depends on 75)

The method of claim 75, wherein the OX40 agonist antibody comprises a VH sequence of SEQ ID NO: 56.

### Claim 177 (depends on 75)

The method of claim 75, wherein the OX40 agonist antibody comprises a VL sequence of SEQ ID NO: 57.

### Claim 178 (depends on 75)

The method of claim 75, wherein the OX40 agonist antibody comprises a VH sequence of SEQ ID NO:56 and a VL sequence of SEQ ID NO: 57.

### Claim 179 (depends on 75)

The method of claim 75, wherein the cancer is lung cancer, glioblastoma, cervical cancer, ovarian cancer, breast cancer, colon cancer, colorectal cancer, fallopian tube cancer, peritoneal cancer, kidney cancer, renal cancer, non-Hodgkins lymphoma, prostate cancer, pancreatic cancer, soft-tissue sarcoma, kaposi's sarcoma, carcinoid carcinoma, head and neck cancer, mesothelioma, multiple myeloma, non-small cell lung cancer, neuroblastoma, melanoma, gastric cancer, or liver cancer.

### Claim 180 (depends on 75)

The method of claim 75, wherein the cancer is a gynecologic cancer

### Claim 181 (depends on 75)

The method of claim 75, wherein the cancer is advanced, refractory, recurrent, chemotherapy-resistant, and/or platinum-resistant.

### Claim 182 (depends on 75)

The method of claim 75, wherein the treatment results in a sustained response in the individual after cessation of the treatment.

### Claim 183 (depends on 75)

The method of claim 75, wherein the individual is a human.
